Get the Stockscreener App
3.20
0.03%
0.171
Xenetic Biosciences Inc stock is traded at $3.20, with a volume of 12,006.
It is up +0.03% in the last 24 hours and up +0.00% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
See More
Previous Close:
$3.029
Open:
$3.04
24h Volume:
12,006
Relative Volume:
0.66
Market Cap:
$7.02M
Revenue:
$2.98M
Net Income/Loss:
$-2.68M
P/E Ratio:
-1.9806
EPS:
-1.6157
Net Cash Flow:
$-2.29M
1W Performance:
+6.88%
1M Performance:
+0.00%
6M Performance:
+17.44%
1Y Performance:
+5.09%
1-Day Range:
$2.98
$3.10
1-Week Range:
$2.75
$3.10
52-Week Range:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.0659 | 6.94M | 2.98M | -2.68M | -2.29M | -1.6157 |
VRTX
Vertex Pharmaceuticals Inc
|
436.97 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.24 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
815.31 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.70 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.00 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesPre-Earnings Drift - Newser
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update - Bez Kabli
Xenetic Biosciences (XBIO) Q2 2025 Earnings Roar: $-0.45 EPS Tops Street ViewCommunity Momentum Stocks - Newser
Xenetic Biosciences (XBIO) Declines -3.75% Amid Market Weakness 2026-05-18Community Watchlist Picks - Newser
Contact Us – Inside INdiana BusinessXenetic Biosciences, Inc.Common Stock (Nasdaq:XBIO) Stock Quote - FinancialContent
TradingKey - TradingKey
Renaissance Holdings Reports 137,440 XBIO Shares (NASDAQ: XBIO) - Stock Titan
Xenetic (XBIO) Reports Strong Q1 Revenue Growth - GuruFocus
Xenetic Virtually Unchanged - Baystreet.ca
Xenetic Biosciences Reports Q1 2026 Results: Advances DNase Oncology Platform, Grows Royalty Revenue, and Strengthens Financial Position - Minichart
Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows - TradingView
Xenetic Biosciences Q1 2026: Royalty Revenue Up 36%, Net Loss Narrows to $0.5M - TradingView
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform - ACCESS Newswire
Xenetic Biosciences (NASDAQ: XBIO) Q1 2026 results show higher royalties, lower loss - Stock Titan
Cancer study OK, smaller loss put Xenetic’s DNase therapy in focus - Stock Titan
Xenetic Biosciences: Q1 Earnings Snapshot - marketscreener.com
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Strategic review and smaller loss at Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
Xenetic’s Next Test: An ASCO Readout And The Cash Question - Finimize
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Times Herald
Xenetic Biosciences Grants Equity Award to Interim CEO - The Globe and Mail
Xenetic Biosciences, Inc. Files Form 8-K Announcing Restricted Stock Award Agreement for CEO James Parslow - Minichart
Xenetic Biosciences, Inc. 2025 Annual Report 10-K/A: Executive Compensation, Governance, and Shareholder Information - Minichart
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting - Times Argus
Xenetic Biosciences (NASDAQ: XBIO) updates CEO pay, ownership in 10-K/A - Stock Titan
Xenetic Biosciences (NASDAQ: XBIO) grants CEO/CFO 100,000 restricted shares - Stock Titan
Xenetic Biosciences (XBIO) interim CEO awarded 100,000-share restricted stock grant - Stock Titan
Cancer drug research from Xenetic gets June poster slot at ASCO - Stock Titan
Xenetic Biosciences (XBIO) Stock: Pricing Analysis (Momentum Fading) 2026-04-20Resistance Breakout - Xã Vĩnh Công
Xenetic Biosciences Inc (XBIOW) - Minichart
Xenetic Biosciences (XBIO) Stock Rallies on Launch (Bullish Sentiment) 2026-04-15Real-time Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Investment Report: Can Xenetic Biosciences Inc maintain sales growth2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Published on: 2026-04-13 21:59:57 - baoquankhu1.vn
XBIO Q2 2025 Earnings: Xenetic Biosciences Inc. beats EPS views, reports zero revenueCrowd Consensus Signals - Newser
History Review: Is Xenetic Biosciences Inc stock good for income investors2026 Patterns & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Sectors Review: Is Xenetic Biosciences Inc stock undervalued right nowTrade Risk Summary & Verified Momentum Watchlists - baoquankhu1.vn
Loss Report: Is Xenetic Biosciences Inc a potential multi baggerWeekly Risk Report & Risk Controlled Stock Alerts - baoquankhu1.vn
XBIO PE Ratio & Valuation, Is XBIO Overvalued - Intellectia AI
XBIO.WS (Xenetic Biosciences) PB Ratio : (As of Apr. 04, 2026) - gurufocus.com
XBIO Q4 Earnings: Beats Estimates by $0.20 - Cổng thông tin điện tử tỉnh Lào Cai
Highs Report: Is now the right time to enter Xenetic Biosciences Inc2026 PreEarnings & Weekly High Conviction Ideas - baoquankhu1.vn
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update - Defense World
Published on: 2026-03-27 18:33:00 - baoquankhu1.vn
Aug Volume: Is Xenetic Biosciences Inc on track to beat earningsQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analyst Calls: Can Xenetic Biosciences Inc be recession proof2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Xenetic (XBIO) Reports Increased Revenue and Advances Clinical D - GuruFocus
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results - Bitget
[8-K] Xenetic Biosciences, Inc. Reports Material Event | XBIO SEC FilingForm 8-K - Stock Titan
Cancer biotech Xenetic grows Takeda royalties to $3M, trims costs - Stock Titan
Xenetic Biosciences: Fourth Quarter Financial Results Overview - Bitget
Xenetic Biosciences 2025 Annual Report: Advancing DNase Immuno-Oncology Technology for Solid Tumors and Strategic Business Developments - Minichart
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):